Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib real-world safety study in advanced non-small cell lung cancer
ChiCTR-OPC-17013445Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Dec 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoint: Safety. Planned start Dec 2017; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OPC-17013445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17013445.